Chapter III. Re-establishing Tolerance

Rev Diabet Stud, 2012, 9(4):319-327 DOI 10.1900/RDS.2012.9.319

Tolerance Strategies Employing Antigen-Coupled Apoptotic Cells and Carboxylated PLG Nanoparticles for the Treatment of Type 1 Diabetes

Suchitra Prasad, Dan Xu, Stephen D. Miller

Department of Microbiology-Immunology and Interdepartmental Immunobiology Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Address correspondence to: Stephen D. Miller, Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Avenue, Chicago, IL 60611, USA,, e-mail:

Manuscript submitted December 15, 2012; resubmitted January 8, 2013; accepted February 8, 2013.

Keywords: type 1 diabetes, immune tolerance, apoptosis, scavenger receptors, poly(lactide-co-glycolide), PLG nanoparticle, anergy, regulatory T cell, transplantation


The development of therapies that specifically target autoreactive immune cells for the prevention and treatment of type 1 diabetes (T1D) without inducing generalized immunosuppression that often compromises the host's ability to clear non-self antigen is highly desired. This review discusses the mechanisms and potential therapeutic applications of antigen-specific T cell tolerance techniques using syngeneic apoptotic cellular carriers and synthetic nanoparticles that are covalently cross-linked to diabetogenic peptides or proteins through ethylene carbodiimide (ECDI) to prevent and treat T1D. Experimental models have demonstrated that intravenous injection of autoantigen decorated splenocytes and biodegradable nanoparticles through ECDI fixation effectively induce and maintain antigen-specific T cell abortive activation and anergy by T cell intrinsic and extrinsic mechanisms. The putative mechanisms include, but are not limited to, the uptake and processing of antigen-coupled nanoparticles or apoptotic cellular carriers for tolerogenic presentation by host splenic antigen-presenting cells, the induction of regulatory T cells, and the secretion of immune-suppressive cytokines, such as IL-10 and TGF-β. The safety profile and efficacy of this approach in preclinical animal models of T1D, including non-obese diabetic (NOD), BDC2.5 transgenic, and humanized mice, have been extensively investigated, and will be the focus of this review. Translation of this approach to clinical trials of T1D and other T cell-mediated autoimmune diseases will also be reviewed in this chapter.

Fulltext: HTML , PDF (530KB)

This article has been cited by other articles:

Toward beta cell replacement for diabetes

Johannesson B, Sui L, Freytes DO, Creusot RJ, Egli D

EMBO J 2015. In press

Therapeutic applications of nanomedicine in autoimmune diseases: From immunosuppression to tolerance induction

Gharagozloo M, Majewski S, Foldvari M

Nanomedicine 2015. In press